STATISTICAL ANALYSIS The analytical approach and power calculations have been published previously, 14 and the com- plete prespecified statistical analysis plan is avail- able with the protocol at NEJM.org. In brief, a formal interim analysis was originally planned when 75% of primary outcome events had oc- curred. However, during the conduct of the trial it became apparent that the interim analysis would occur close to the end of the trial. The executive committee therefore decided to remove the in- terim analysis from the protocol. We estimated that 681 primary outcome events would be needed to detect a 22% lower relative risk in the dapagliflozin group than in the placebo group (hazard ratio of 0.78), with 90% power using a two-sided alpha level of 0.05 and assuming an annual event rate for the primary outcome of 7.5% in the placebo group. A closed testing pro- cedure that included a prespecified hierarchical order of the primary and secondary outcomes was used to ensure control of type I error at a two-sided 0.05 level.

Glencoe Algebra 1, Student Edition, 9780079039897, 0079039898, 2018
18th Edition
ISBN:9780079039897
Author:Carter
Publisher:Carter
Chapter10: Statistics
Section10.6: Summarizing Categorical Data
Problem 30PPS
icon
Related questions
Question
100%

I need help dissecting this (attached) in layman's terms.

Statistical Analysis-

The analytical approach and power calculations
have been published previously,14 and the complete
prespecified statistical analysis plan is available
with the protocol at NEJM.org. In brief, a
formal interim analysis was originally planned
when 75% of primary outcome events had occurred.
However, during the conduct of the trial it
became apparent that the interim analysis would
occur close to the end of the trial. The executive
committee therefore decided to remove the interim
analysis from the protocol. We estimated
that 681 primary outcome events would be
needed to detect a 22% lower relative risk in the
dapagliflozin group than in the placebo group
(hazard ratio of 0.78), with 90% power using a
two-sided alpha level of 0.05 and assuming an
annual event rate for the primary outcome of
7.5% in the placebo group. A closed testing procedure
that included a prespecified hierarchical
order of the primary and secondary outcomes
was used to ensure control of type I error at a
two-sided 0.05 level.

STATISTICAL ANALYSIS
The analytical approach and power calculations
have been published previously, 14 and the com-
plete prespecified statistical analysis plan is avail-
able with the protocol at NEJM.org. In brief, a
formal interim analysis was originally planned
when 75% of primary outcome events had oc-
curred. However, during the conduct of the trial it
became apparent that the interim analysis would
occur close to the end of the trial. The executive
committee therefore decided to remove the in-
terim analysis from the protocol. We estimated
that 681 primary outcome events would be
needed to detect a 22% lower relative risk in the
dapagliflozin group than in the placebo group
(hazard ratio of 0.78), with 90% power using a
two-sided alpha level of 0.05 and assuming an
annual event rate for the primary outcome of
7.5% in the placebo group. A closed testing pro-
cedure that included a prespecified hierarchical
order of the primary and secondary outcomes
was used to ensure control of type I error at a
two-sided 0.05 level.
Transcribed Image Text:STATISTICAL ANALYSIS The analytical approach and power calculations have been published previously, 14 and the com- plete prespecified statistical analysis plan is avail- able with the protocol at NEJM.org. In brief, a formal interim analysis was originally planned when 75% of primary outcome events had oc- curred. However, during the conduct of the trial it became apparent that the interim analysis would occur close to the end of the trial. The executive committee therefore decided to remove the in- terim analysis from the protocol. We estimated that 681 primary outcome events would be needed to detect a 22% lower relative risk in the dapagliflozin group than in the placebo group (hazard ratio of 0.78), with 90% power using a two-sided alpha level of 0.05 and assuming an annual event rate for the primary outcome of 7.5% in the placebo group. A closed testing pro- cedure that included a prespecified hierarchical order of the primary and secondary outcomes was used to ensure control of type I error at a two-sided 0.05 level.
Expert Solution
steps

Step by step

Solved in 2 steps

Blurred answer
Similar questions
  • SEE MORE QUESTIONS
Recommended textbooks for you
Glencoe Algebra 1, Student Edition, 9780079039897…
Glencoe Algebra 1, Student Edition, 9780079039897…
Algebra
ISBN:
9780079039897
Author:
Carter
Publisher:
McGraw Hill
College Algebra (MindTap Course List)
College Algebra (MindTap Course List)
Algebra
ISBN:
9781305652231
Author:
R. David Gustafson, Jeff Hughes
Publisher:
Cengage Learning
College Algebra
College Algebra
Algebra
ISBN:
9781938168383
Author:
Jay Abramson
Publisher:
OpenStax